946 related articles for article (PubMed ID: 33768612)
1. QT prolongation associated with hydroxychloroquine and protease inhibitors in COVID-19.
Koh HM; Chong PF; Tan JN; Chidambaram SK; Chua HJ
J Clin Pharm Ther; 2021 Jun; 46(3):800-806. PubMed ID: 33768612
[TBL] [Abstract][Full Text] [Related]
2. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE
JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708
[TBL] [Abstract][Full Text] [Related]
3. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
Mercuro NJ; Yen CF; Shim DJ; Maher TR; McCoy CM; Zimetbaum PJ; Gold HS
JAMA Cardiol; 2020 Sep; 5(9):1036-1041. PubMed ID: 32936252
[TBL] [Abstract][Full Text] [Related]
4. Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings.
Gasperetti A; Biffi M; Duru F; Schiavone M; Ziacchi M; Mitacchione G; Lavalle C; Saguner A; Lanfranchi A; Casalini G; Tocci M; Fabbricatore D; Salghetti F; Mariani MV; Busana M; Bellia A; Cogliati CB; Viale P; Antinori S; Galli M; Galiè N; Tondo C; Forleo GB
Europace; 2020 Dec; 22(12):1855-1863. PubMed ID: 32971536
[TBL] [Abstract][Full Text] [Related]
5. Absence of relevant QT interval prolongation in not critically ill COVID-19 patients.
Jiménez-Jáimez J; Macías-Ruiz R; Bermúdez-Jiménez F; Rubini-Costa R; Ramírez-Taboada J; Flores PIG; Gallo-Padilla L; García JDM; García CM; Suárez SM; Molina CF; López MÁ; Tercedor L
Sci Rep; 2020 Dec; 10(1):21417. PubMed ID: 33293554
[TBL] [Abstract][Full Text] [Related]
6. Hydroxychloroquine cardiotoxicity: a case-control study comparing patients with COVID-19 and patients with systemic lupus erythematosus.
Mancuso S; Spinelli FR; Agati L; Ciardi MR; Garufi C; Natalucci F; Molteni E; Truglia S; Riccieri V; Priori R; Mastroianni CM; Conti F
Clin Exp Rheumatol; 2022 May; 40(5):890-896. PubMed ID: 35383554
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Safety of Hydroxychloroquine-Azithromycin in 424 COVID-19 Patients.
Million M; Lagier JC; Hourdain J; Franceschi F; Deharo JC; Parola P; Brouqui P
Medicina (Kaunas); 2023 Apr; 59(5):. PubMed ID: 37241095
[No Abstract] [Full Text] [Related]
8. The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients.
Bakhshaliyev N; Uluganyan M; Enhos A; Karacop E; Ozdemir R
J Electrocardiol; 2020; 62():59-64. PubMed ID: 32827987
[TBL] [Abstract][Full Text] [Related]
9. Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients.
Eftekhar SP; Kazemi S; Barary M; Javanian M; Ebrahimpour S; Ziaei N
Cardiovasc Ther; 2021; 2021():6683098. PubMed ID: 33688374
[TBL] [Abstract][Full Text] [Related]
10. Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.
Ding J; Liu W; Guan H; Feng Y; Bao Y; Li H; Wang X; Zhou Z; Chen Z
Medicine (Baltimore); 2021 Jul; 100(28):e26538. PubMed ID: 34260531
[TBL] [Abstract][Full Text] [Related]
11. Effects of hydroxychloroquine treatment on QT interval.
Hooks M; Bart B; Vardeny O; Westanmo A; Adabag S
Heart Rhythm; 2020 Nov; 17(11):1930-1935. PubMed ID: 32610165
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19.
Özdemir İH; Özlek B; Özen MB; Gündüz R; Çetin N; Bilge AR
Int J Clin Pract; 2021 Feb; 75(2):e13896. PubMed ID: 33280207
[TBL] [Abstract][Full Text] [Related]
13. QTc prolongation among hydroxychloroquine sulphate-treated COVID-19 patients: An observational study.
Fteiha B; Karameh H; Kurd R; Ziff-Werman B; Feldman I; Bnaya A; Einav S; Orlev A; Ben-Chetrit E
Int J Clin Pract; 2021 Mar; 75(3):e13767. PubMed ID: 33063447
[TBL] [Abstract][Full Text] [Related]
14. Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.
Bernardini A; Ciconte G; Negro G; Rondine R; Mecarocci V; Viva T; Santini F; de Innocentiis C; Giannelli L; Witkowska E; Locati ET; Castelvecchio S; Marrocco-Trischitta MM; Vicedomini G; Menicanti L; Pappone C
Int J Cardiol; 2021 Feb; 324():242-248. PubMed ID: 32956782
[TBL] [Abstract][Full Text] [Related]
15. QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.
Bun SS; Taghji P; Courjon J; Squara F; Scarlatti D; Theodore G; Baudouy D; Sartre B; Labbaoui M; Dellamonica J; Doyen D; Marquette CH; Levraut J; Esnault V; Bun SS; Ferrari E
Clin Pharmacol Ther; 2020 Nov; 108(5):1090-1097. PubMed ID: 32588427
[TBL] [Abstract][Full Text] [Related]
16. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
Ramireddy A; Chugh H; Reinier K; Ebinger J; Park E; Thompson M; Cingolani E; Cheng S; Marban E; Albert CM; Chugh SS
J Am Heart Assoc; 2020 Jun; 9(12):e017144. PubMed ID: 32463348
[TBL] [Abstract][Full Text] [Related]
17. Why we should be more careful using hydroxychloroquine in influenza season during COVID-19 pandemic?
Çelik HG; Keske Ş; Şener Ü; Tekbaş M; Kapmaz M; Şahin ŞT; Özyıldırım A; Aytekin S; Aytekin V; Ergönül Ö
Int J Infect Dis; 2021 Jan; 102():389-391. PubMed ID: 33130195
[TBL] [Abstract][Full Text] [Related]
18. Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19.
Seyhan AU; Doganay F; Yilmaz E; Topal NP; Ak R
J Coll Physicians Surg Pak; 2020 Oct; 30(10):153-157. PubMed ID: 33291194
[TBL] [Abstract][Full Text] [Related]
19. Changes in QTc interval after hydroxychloroquine therapy in patients with COVID-19 infection: a large, retrospective, multicentre cohort study.
El Kadri M; Al Falasi O; Ahmed R; Al Awadhi A; Altaha Z; Hillis A; Panikkaveetil B; Abdalla S; Ansel Benette H; Almubarak A; Saifuddin M; Alattar Y; Oulhaj A; AlKaabi S
BMJ Open; 2022 Feb; 12(2):e051579. PubMed ID: 35140148
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M;
Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
